Flex Pharma Company Profile (NASDAQ:FLKS)

Analyst Ratings

Consensus Ratings for Flex Pharma (NASDAQ:FLKS) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $24.00 (101.85% upside)

Analysts' Ratings History for Flex Pharma (NASDAQ:FLKS)
Show:
DateFirmActionRatingPrice TargetActions
6/10/2016Jefferies GroupReiterated RatingBuy$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/3/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2016Piper Jaffray Cos.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/12/2016Roth CapitalLower Price Target$27.00 -> $24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2015JMP SecuritiesInitiated CoverageOutperform$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Flex Pharma (NASDAQ:FLKS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/4/2016Q1($0.56)($0.61)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/8/2016Q415($0.56)($0.51)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2015Q315($0.44)($0.53)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.37)($0.47)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q1($0.29)($0.59)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2015Q4($0.12)($1.82)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Flex Pharma (NASDAQ:FLKS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.46)($0.46)($0.46)
Q2 20162($0.62)($0.52)($0.57)
Q3 20162($0.62)($0.55)($0.59)
Q4 20162($0.67)($0.61)($0.64)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Flex Pharma (NASDAQ:FLKS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Flex Pharma (NASDAQ:FLKS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/23/2016Christoph H WestphalCEOBuy2,700$11.28$30,456.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/22/2016Christoph H WestphalCEOBuy5,700$11.05$62,985.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/21/2016Christoph H WestphalCEOBuy2,800$11.07$30,996.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2016Christoph H WestphalCEOBuy6,000$11.18$67,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2016Christoph H WestphalCEOBuy5,800$11.17$64,786.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/14/2016Christoph H WestphalCEOBuy5,900$11.54$68,086.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2016Christoph H WestphalCEOBuy6,000$11.94$71,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2016Christoph H WestphalCEOBuy5,900$12.25$72,275.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2016Christoph H WestphalCEOBuy6,000$12.56$75,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2016Christoph H WestphalCEOBuy10,000$12.99$129,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/31/2016Christoph H WestphalCEOBuy22,300$12.68$282,764.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/26/2016Christoph H WestphalCEOBuy28,600$12.84$367,224.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/24/2016Christoph H WestphalCEOBuy30,334$12.42$376,748.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2016Christoph H WestphalCEOBuy7,914$11.06$87,528.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2016Christoph H WestphalCEOBuy33,400$11.10$370,740.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016Christoph H WestphalCEOBuy15,469$10.25$158,557.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2016Christoph H WestphalCEOBuy30,217$10.12$305,796.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/10/2016Christoph H WestphalCEOBuy30,109$9.94$299,283.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/24/2016Christoph H WestphalCEOBuy49,563$11.06$548,166.78View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/22/2016Christoph H WestphalCEOBuy23,951$11.78$282,142.78View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2016Christoph H WestphalCEOBuy48,058$11.74$564,200.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2016Christoph H WestphalCEOBuy37,574$11.00$413,314.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2016Christoph H WestphalCEOBuy38,379$10.23$392,617.17View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2016Michelle StacyDirectorBuy2,585$9.63$24,893.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2016Thomas WesselInsiderBuy20,000$7.94$158,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2016Christoph H WestphalCEOBuy89,680$7.00$627,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2016Roderick MackinnonDirectorBuy10,000$7.03$70,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/14/2015Christoph H WestphalCEOBuy927$12.01$11,133.27View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/7/2015Christoph H WestphalCEOBuy907$12.02$10,902.14View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2015Marc D KozinDirectorBuy4,500$11.38$51,210.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2015Christoph H WestphalCEOBuy1,001$10.78$10,790.78View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/9/2015Christoph H WestphalCEOBuy1,000$11.03$11,030.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/26/2015Christoph H WestphalCEOBuy1,043$10.55$11,003.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/19/2015Christoph H WestphalCEOBuy1,018$10.61$10,800.98View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/28/2015Christoph H WestphalCEOBuy924$11.18$10,330.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/30/2015Christoph H WestphalCEOBuy272$20.52$5,581.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Flex Pharma (NASDAQ:FLKS)
DateHeadline
07/24/16 08:33 AMIs $40 Price Target Attainable For Flex Pharma, Inc. (NASDAQ:FLKS)? - Investor Newswire
07/22/16 04:55 AMFlex Pharma, Inc. (NASDAQ:FLKS): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/21/16 07:34 AMCould Flex Pharma Inc Change Direction After Today's Huge Increase? - Consumer Eagle
07/19/16 09:18 PMEarnings Focus and Crowd Sourced Sentiment Review for Flex Pharma, Inc. (NASDAQ:FLKS) - TGP
07/19/16 09:18 PMEquity Roundup: Stock Performance Focus on Flex Pharma, Inc. (NASDAQ:FLKS) - Press Telegraph
07/18/16 04:13 PMInvestor Watch: Volatility Recap on Shares of: Flex Pharma, Inc. (NASDAQ:FLKS) - Engelwood Daily
07/18/16 04:13 PMInsider Trader Watch: Flex Pharma Inc (NASDAQ:FLKS) - The Voice Registrar
07/17/16 03:42 PMStrong Sell Calls For Flex Pharma, Inc. (NASDAQ:FLKS) At 0 - Investor Newswire
07/17/16 03:42 PMNext Weeks Broker Price Targets For Flex Pharma, Inc. (FLKS) - Fiscal Standard
07/14/16 09:23 PMFlex Pharma, Inc. (NASDAQ:FLKS) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/14/16 09:23 PMEye on Stock Volatility for: Flex Pharma, Inc. (NASDAQ:FLKS) - Engelwood Daily
07/14/16 07:22 AMAnalyst Target and Average Rating Watch: Flex Pharma, Inc. (NASDAQ:FLKS) - Press Telegraph
07/14/16 07:22 AMInsiders Increasing Positions in: Flex Pharma, Inc. (NASDAQ:FLKS) - Press Telegraph
07/13/16 04:23 PMShare Volatility Watch for: Flex Pharma, Inc. (NASDAQ:FLKS) - Engelwood Daily
07/12/16 09:23 PMA New Way to Prevent Muscle Cramps
07/12/16 08:28 AMFlex Pharma, Inc. (NASDAQ:FLKS) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/10/16 08:32 AMIs $40 Within Reach For Flex Pharma, Inc. (NASDAQ:FLKS)? - Investor Newswire
07/10/16 08:32 AMFlex Pharma, Inc. (FLKS) Broker Price Targets For The Coming Week - Fiscal Standard
07/08/16 05:16 AMCan Flex Pharma, Inc. (NASDAQ:FLKS) Improve on the Earnings Front? - Engelwood Daily
07/08/16 05:16 AMBroker Outlook For Flex Pharma, Inc. (FLKS) - Fiscal Standard
07/06/16 09:51 PMCompany Stock Focus for Flex Pharma, Inc. (NASDAQ:FLKS): Which Way Will Shares Head? - Press Telegraph
07/06/16 04:07 PMPerformance Recap and Target Perspective on Flex Pharma, Inc. (NASDAQ:FLKS) - Press Telegraph
07/06/16 08:45 AMThis Weeks Broker Price Targets For Flex Pharma, Inc. (FLKS) - Fiscal Standard
07/06/16 08:45 AMFlex Pharma to Present at the Cantor Fitzgerald Healthcare Conference - Yahoo Finance
07/06/16 07:51 AMFlex Pharma to Present at the Cantor Fitzgerald Healthcare Conference - [at noodls] - BOSTON--(BUSINESS WIRE)--Jul. 6, 2016-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS) today announced that Company management will present a corporate overview at the 2 Annual Cantor Fitzgerald Healthcare ...
07/02/16 03:56 PMFlex Pharma, Inc. (NASDAQ:FLKS) Expected to Reach Highs Of $40 - Investor Newswire
07/01/16 04:02 PMTracking Stock Volatility for: Flex Pharma, Inc. (NASDAQ:FLKS) - Engelwood Daily
06/30/16 05:14 AMFlex Pharma: What A Load Of Cramp - Seeking Alpha
06/28/16 09:01 PMCheck on Share Volatility: Flex Pharma, Inc. (NASDAQ:FLKS) - Engelwood Daily
06/26/16 03:36 PMFlex Pharma Incorporated (NASDAQ:FLKS) Sellers Increased By 12.96% Their Shorts - Engelwood Daily
06/26/16 03:36 PMStrong Sell Calls Recommendations For Flex Pharma, Inc. (NASDAQ:FLKS) At 0 - Investor Newswire
06/23/16 04:28 AMFlex Pharma, Inc. (NasdaqGM:FLKS) Stock Momentum Hits Weakness - CML News
06/19/16 03:47 PMFlex Pharma, Inc. (FLKS) Analyst Price Targets For The Coming Week - Fiscal Standard
06/18/16 08:31 AMHere's What You Need To Know About The Flex Pharma Inc (NASDAQ:FLKS) MS Trial - Market Exclusive
06/17/16 03:51 PMHere’s What You Need To Know About The Flex Pharma Inc (NASDAQ:FLKS) MS Trial
06/15/16 04:05 PMFlex Pharma (FLKS) Commences FLX-787 Phase 2 in Australia as MS Treatment - StreetInsider.com
06/15/16 08:45 AMFlex Pharma (FLKS) Commences FLX-787 Phase 2 in Australia as MS Treatment
06/15/16 07:19 AMFlex Pharma Initiates Phase 2 Efficacy Study in Multiple Sclerosis - [at noodls] - -- FLX-787, A Single Molecule, Synthesized, TRP Ion Channel Activator, in Randomized, Controlled, Cross-over Study -- BOSTON--(BUSINESS WIRE)--Jun. 15, 2016-- Click to Tweet this News Flex Pharma, Inc. ...
06/06/16 01:26 PMFlex Pharma, Inc. :FLKS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 -
06/04/16 09:25 PMFlex Pharma's (FLKS) “Buy” Rating Reiterated at Cantor Fitzgerald - Let Me Know About This
06/03/16 10:13 PMFlex Pharma Inc (FLKS) Receives Buy Rating from Piper Jaffray - Let Me Know About This
06/03/16 04:16 PMStock Review and Earnings Check on Flex Pharma, Inc. (NASDAQ:FLKS) - HNN
06/03/16 04:16 PMHC Wainwright Reiterates Buy Rating for Flex Pharma Inc (FLKS) - Let Me Know About This
06/03/16 04:16 PMHC Wainwright Reiterates Buy Rating for Flex Pharma Inc (FLKS) - Let Me Know About This
06/03/16 07:25 AMFlex Pharma Presenting at Upcoming Investor Conferences in June 2016 - [at noodls] - BOSTON--(BUSINESS WIRE)--Jun. 3, 2016-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS) today announced that it will present a corporate overview at the following upcoming investor conferences in June: ...
06/03/16 06:41 AMFlex Pharma Launches First Consumer Product Scientifically Proven to Prevent and Treat Muscle Cramps - Business Wire (press release) - Flex Pharma Launches First Consumer Product Scientifically Proven to Prevent and Treat Muscle CrampsBusiness Wire (press release)Flex Pharma, Inc. (NASDAQ: FLKS), today announced that it has launched its cornerstone consumer product, HOTSHOT™, the first scientifically proven formula to prevent and treat muscle cramps, on its branded website www.TeamHOTSHOT.com.Broker Watchlist: Flex Pharma, Inc. (FLKS)Share Trading NewsFlex Pharma, Inc. (FLKS) Files Form 4 Insider Buying : Christoph H Westphal Buys 22300 SharesMarket DigestFlex Pharma Launches New Muscle Cramp Therapy HOTSHOT (NASDAQ:FLKS)Sonoran Weekly ReviewThe Post -Analyst Ratingsall 6 news articles »
06/02/16 04:12 PMFlex Pharma, Inc. (NASDAQ:FLKS) Stock Update & Estimates - Stock Tick Tock - Flex Pharma, Inc. (NASDAQ:FLKS) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Flex Pharma, Inc. (NASDAQ:FLKS) to post earnings of $-0.73 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be issued ...and more »
06/02/16 04:12 PMBroker Watchlist: Flex Pharma, Inc. (FLKS) - Share Trading News - Broker Watchlist: Flex Pharma, Inc. (FLKS)Share Trading NewsThey now have a USD 25 price target on the stock. 02/23/2015 – JMP Securities began new coverage on Flex Pharma, Inc. giving the company a “outperform” rating. The share price of Flex Pharma, Inc. (FLKS) was up +5.20% during the last trading session, ...Flex Pharma Launches First Consumer Product Scientifically Proven to Prevent and Treat Muscle CrampsBusiness Wire (press release)Flex Pharma, Inc. (FLKS) Files Form 4 Insider Buying : Christoph H Westphal Buys 22300 SharesMarket DigestTime to Buy Flex Pharma Inc After Today's Huge Increase?The PostAnalyst Ratings -Sonoran Weekly Reviewall 6 news articles »
06/02/16 07:00 AMScientific Breakthrough In Sports Nutrition To Change The Game For Millions Of Endurance Athletes - [PR Newswire] - BOSTON, June 2, 2016 /PRNewswire/ -- Exercise-associated muscle cramps are agonizing. Breakthrough research, to be presented today at the American College of Sports Medicine's Annual Meeting and published in the Journal of the American Medical Athletic Association later this month, has led to the development of a revolutionary new sports shot, HOTSHOT™, that is scientifically proven to prevent and treat muscle cramps by stopping them where they start: at the nerve. Invented by a Nobel Prize-winning neuroscientist and endurance athlete in collaboration with a Harvard Medical School neurobiology professor, HOTSHOT, previously codenamed #ITSTHENERVE, is a 1.7 fluid ounce sports shot comprised of a proprietary formula of GMO-free organic ingredients with a kick.
06/02/16 06:55 AMFlex Pharma Launches First Consumer Product Scientifically Proven to Prevent and Treat Muscle Cramps - [at noodls] - -- Harvard Medical School Professor, Dr. Bruce Bean, and Flex CMO, Dr. Tom Wessel, Presenting at American College of Sport Medicine Symposium -- BOSTON--(BUSINESS WIRE)--Jun. 2, 2016-- Flex Pharma, Inc. ...

Social

About Flex Pharma

Flex Pharma logoFlex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company's product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company's lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: FLKS
  • CUSIP:
Key Metrics:
  • Previous Close: $11.89
  • 50 Day Moving Average: $11.29
  • 200 Day Moving Average: $10.30
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $190.47M
  • Beta: 2.89
  • Current Year EPS Consensus Estimate: $-2.56 EPS
  • Next Year EPS Consensus Estimate: $-2.89 EPS
Additional Links:
Flex Pharma (NASDAQ:FLKS) Chart for Monday, July, 25, 2016